• Users Online: 439
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2022  |  Volume : 13  |  Issue : 3  |  Page : 111-117

Approaches to acquired thrombotic thrombocytopenic purpura management in Saudi Arabia


1 Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia
2 Department of Adult Hematology, King Faisal Specialist Hospital and Research Center, Madinah, Saudi Arabia
3 Department of Adult Hematology and Stem Cell Transplantation, King Fahad Specialist Hospital, Dammam, Saudi Arabia
4 Department of Hematology and Bone Marrow Transplantation Section, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
5 Department of Adult Hematology/BMT, King Fahad Medical City, Riyadh, Saudi Arabia
6 Department of Adult Hematology/BMT, King Abdulaziz Medical City, Jeddah, Saudi Arabia
7 Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia
8 Department of Adult Hematology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
9 Department of Medical Affairs, Sanofi, Jeddah, Saudi Arabia
10 Department of Medical Affairs, Sanofi, Dubai, UAE
11 Department of Hematology, Faculty of Medicine, King Abdulaziz University Hospital, Jeddah, Saudi Arabia

Correspondence Address:
Dr. Ayman AlHejazi
Department of Oncology, King Abdulaziz Medical City, Riyadh 14611
Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/joah.joah_46_21

Rights and Permissions

Acquired thrombotic thrombocytopenic purpura (aTTP) is a life-threatening microangiopathy usually characterized by microangiopathic hemolytic anemic, thrombocytopenia, and end-organ ischemia associated with disseminated microvascular platelet-rich thrombi and severe deficiency (activity <10%) of A Disintegrin-like And Metalloprotease with ThromboSpondin Type 1 Motif No. 13 (ADAMTS13). It is a medical emergency, and if left untreated, acute mortality is as high as 90%. This review article is a narrative review based on available literature. In addition, the key discussions of the Kingdom of Saudi Arabia experts and members of “Approaches to aTTP Management” Advisory Board meeting held on October 16, 2020, have been incorporated as expert opinions. It was agreed that treatment should be started based on the presumptive diagnosis and continued until remission or an alternate diagnosis is established. Use of caplacizumab in addition to therapeutic plasma exchange and immunosuppression is recommended in confirmed aTTP episodes.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed815    
    Printed6    
    Emailed0    
    PDF Downloaded168    
    Comments [Add]    

Recommend this journal